Cancer cells that maintain the capacity of TGF-β signaling capitalize on platforms that induce plasticity, such as epithelial-to-mesenchymal transition (EMT) and stem-like self-renewal, which lead to composition and remodeling of the TME and immune evasion. This evidence concerns the gene TGFB1 and cancer.